Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.58 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11169517 | 0.98 | PKM (0.57) | PKMPTK2BCDC25BNEU3SMN1; SMN2 | |
| SCHEMBL29787231 | 0.85 | NEU3 (0.57) | PKMPTK2BCDC25BNEU3SMN1; SMN2 | |
| SCHEMBL2778224 | 0.85 | ACLY (0.51) | PKMPTK2BNEU3SMN1; SMN2CA1 | |
| SCHEMBL2777527 | 0.85 | NEU3 (0.57) | PKMPTK2BCDC25BNEU3SMN1; SMN2 | |
| SCHEMBL11169516 | 0.84 | PTK2B (0.42) | PKMPTK2BNEU3SMN1; SMN2CA1 | |
| SCHEMBL11533341 | 0.84 | CA2 (0.46) | PKMPTK2BCA1CA2CA9 | |
| SCHEMBL2593426 | 0.81 | PTK2B (0.58) | PKMPTK2BCDC25BSMN1; SMN2HTT | |
| SCHEMBL29403183 | 0.81 | PTK2B (0.58) | PKMPTK2BCDC25BSMN1; SMN2HTT | |
| SCHEMBL940353 | 0.81 | PTK2B (0.58) | PKMPTK2BCDC25BSMN1; SMN2HTT | |
| SCHEMBL20647086 | 0.80 | KDM4E (0.50) | PKMPTK2BCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-9738599-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9738599-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9738599-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9718781-B2 | Methods and compounds for treating proliferative disorders and viral infections | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-01 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054581-A2 | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| CN-1049888-C | Benzoylguanidine, process for preparing same, their use as medicine and medicine containing same | HOECHST AG (DE) | 2000-03-01 | — | — | CN | disclosed |
| EP-0416499-B1 | Benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them | HOECHST AG (DE) | 1995-04-26 | — | — | EP | disclosed |
| US-5292755-A | USPA benzolyguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-08 | — | — | US | disclosed |
| US-5091394-A | BENZOYLGUANIDINES, A PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND MEDICAMENTS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| CN-1050018-A | Benzoylguanidines, they the preparation method, they are as the application of medicament and the medicament that contains them | HOECHST AG (DE) | 1991-03-20 | — | — | CN | disclosed |
| EP-0416499-A2 | Benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-13 | — | — | EP | disclosed |
| EP-0068407-A1 | Aminosulfonylbenzoic acid derivatives | HODOGAYA CHEMICAL CO., LTD. (JP) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | TBXA2R, PTGFR, TBXAS1 | PKM 938/4885PTK2B 717/4885CDC25B 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.